Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04221035
Title High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Gustave Roussy, Cancer Campus, Grand Paris
Indications

neuroblastoma

Therapies

Busulfan + Melphalan + Thiotepa

Dinutuximab beta

Cisplatin + Etoposide + Vindesine

Dacarbazine + Doxorubicin + Ifosfamide + Vincristine Sulfate

Carboplatin + Cisplatin + Cyclophosphamide + Etoposide + Vincristine Sulfate

Busulfan + Melphalan

Age Groups: child | adult
Covered Countries


No variant requirements are available.